Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TCM Biotech InternationalTPE:4169 -2.23%52 Days Payable is 45.85 as of Mar. 2026, which is 7% below its 10-year median of 49.09. GuruFocus rates TPE:4169 with a GF Score™ of 52/100 and a GF Value™ of NT$42.30 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 704 Biotechnology companies, TCM Biotech International ranks worse than 74.01% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:4169 vs VRTX, REGN, RVMD: Days Payable Comparison
For the Biotechnology subindustry, TCM Biotech International's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TCM Biotech International Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, TCM Biotech International's Days Payable distribution charts can be found below:
* The bar in red indicates where TCM Biotech International's Days Payable falls into.
TCM Biotech International Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
TCM Biotech International's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TCM Biotech International (TPE:4169) has a Days Payable of 45.85 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on TCM Biotech International and its competitors. This is near median its historical median of 49.09. Over the past decade, TCM Biotech International's Days Payable has ranged from 27.62 to 64.86. According to the industry distribution chart, TCM Biotech International ranks #521 out of 704 companies in the Biotechnology industry, placing it in the top 74%.
Is TCM Biotech International's Days Payable too high?
TCM Biotech International's current Days Payable of 45.85 is near median its 10-year median of 49.09. Over the past 10 years, this metric has ranged from a low of 27.62 to a high of 64.86. The Biotechnology industry median Days Payable is 112.72. TCM Biotech International's value of 45.85 is 59.3% below this industry median. Based on the distribution chart, TCM Biotech International ranks #521 out of 704 companies in the Biotechnology industry, which is below the industry midpoint. Overall, TCM Biotech International has a GF Score™ of 52/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does TCM Biotech International's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, TCM Biotech International ranks #521 out of 704 companies for Days Payable. This places TCM Biotech International in the lower half of its industry. The industry median Days Payable is 112.72. TCM Biotech International's value of 45.85 is 59.3% below this benchmark. Historically, TCM Biotech International's own Days Payable has ranged from 27.62 to 64.86 over the past decade. While the company's 10-year median is 49.09 vs. the industry median of 112.72, TCM Biotech International has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.72, based on 704 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TCM Biotech International's current Days Payable of 45.85 is 59.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on TCM Biotech International and its competitors. For the Biotechnology industry, the median Days Payable is 112.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TCM Biotech International's current Days Payable is 45.85, which is near median its own 10-year median of 49.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TCM Biotech International stock overvalued right now?
Based on GuruFocus' analysis, TCM Biotech International (TPE:4169) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$42.30, compared to a current price of NT$153.50 — trading 262.9% above its estimated fair value. The current Days Payable is 45.85, which is near median its 10-year median of 49.09 and 59.3% below the Biotechnology industry median of 112.72. TCM Biotech International's overall GF Score™ is 52/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For TCM Biotech International (TPE:4169), the current Days Payable is 45.85 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TCM Biotech International (TPE:4169) Overvalued in 2026?
Based on GuruFocus' analysis, TCM Biotech International stock appears to be overvalued.
The current stock price of NT$153.50 is trading 262.9% above its estimated GF Value™ of NT$42.30.
GuruFocus considers TCM Biotech International to be Significantly Overvalued.
Key valuation signals for TPE:4169:
Days Payable: 45.85 (near median its 10-year median of 49.09)
GF Value™: NT$42.30 vs. price of NT$153.50 (262.9% above fair value)
Industry Position: 59.3% below the Biotechnology median (#521 of 704)
No single metric tells the full story. See the TPE:4169 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TCM Biotech International Corp is a Taiwan based biotechnology company. It is engaged in research and development of new biotech drugs, development of microbial strain cultivation and fermentation technology, biotechnology services, wholesale of medical equipment, and sales of functional foods. Its products includes medical equipment, medical testing platform, medical drugs, and others. The Group has two reportable segments: Segment A and Segment B. Segment A is the functional foods segment, while Segment B is the pharmaceuticals segment. It derives maximum revenue from pharmaceuticals segment. Geographically, the company operates in Taiwan and Other countries, of which it generates maximum revenue from Taiwan.
52GF Score
Get the complete analysis for TPE:4169
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:4169 has been successfully added to your 
